When it comes to heart health, heart attacks tend to get the spotlight. While 805,000 people die from heart attacks every ...
The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...
Since 2019, three disease-specific therapies have been approved to treat patients with ATTR-CM. The first was Pfizer’s Vyndamax (tafamidis) in May 2019, which was approved for both wild type and ...
Heart failure in which left ventricular ejection fraction recovers into the normal range has many unknowns. Andrew Perry, MD, discusses key management strategies with Jane Wilcox, MD, of Northwestern ...
The diagnosis of a potentially lethal cardiovascular disease in a young athlete presents a complex dilemma regarding athlete safety, patient autonomy, team or institutional risk tolerance and medical ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...
Heart failure is a progressive disease in which the myocardium weakens and cannot pump efficiently (systolic dysfunction) or fill adequately (diastolic dysfunction). Obesity has an important influence ...
Scientists develop new blood test to identify individuals at high risk of developing hypertrophic cardiomyopathy, most common ...
Chevy Chase and his loved ones are opening up about the eight days he spent in a medically induced coma amid his near-fatal ...
His daughter, Caley Chase, said that he doesn’t recall any of the incidents because he “came back from the dead,” bringing up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results